type 2 diabetes and semaglutide Ozempic® (semaglutide) GLP-1 RA for Oral Semaglutide GLP-1 for Type

Patients should be aware that key safety considerations include: Hypersensitivity to the active substance or excipients Pregnancy or breastfeeding Risk of pancreatitis and gallbladder disease Potential for dehydration with severe gastrointestinal side effects A thorough medical assessment, including review of current medications and comorbidities, is essential before initiating treatment

S., Amaro, A., & Wadden, T

(d) On the axial apparent diffusion coefficient (ADC) map, the lesion displays low signal intensity, confirming diffusion restriction

Glycaemic efficacy is enhanced when these agents are used together, with clinical trials demonstrating HbA1c reductions typically around 10-20 mmol/mol (1-2%) from baseline, depending on starting values and specific agents used

Eating disorders Pre-clinical and mechanistic studies We retrieved only a few pre-clinical and mechanistic articles relevant to GLP-1RAs for eating disorders (Supplementary Section 5)

Temperature cycling